Jerrold Vitek, MD, PhD University of Minnesota, Minneapolis, MN, discusses the 4-year follow-up analysis of the INTREPID trial (NCT01839396). This trial evaluated the safety and effectiveness of a novel Deep Brain Stimulation (DBS) device capable of Multiple Independent Current Control (MICC) in the treatment of patients with advanced, levodopa-responsive bilateral Parkinson’s disease (PD), which is not adequately controlled with medication. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.